Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01882504 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
A Phase 2 study of Pyoderma Gangrenosum, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 19
- Study locations
NCT01882504: Completed Phase 2 study of Pyoderma Gangrenosum, sponsored by Xoma (US).
NCT01882504 is a Phase 2 study of Pyoderma Gangrenosum that has completed, run by Xoma (US). The registered enrollment target is 8 participants, below the 37-participant average among 3 other Pyoderma Gangrenosum trials with a reported enrollment target (78% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01882504, a Phase 2 study of Pyoderma Gangrenosum, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 19
- Study locations
Study Summary
The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
Conditions Studied
Interventions
- DRUG gevokizumab
Study Locations (19)
Texas
- - Arlington
- - Dallas
- - Houston
Florida
- - Miami
- - Miami Shores
Ohio
- - Cleveland
- - Columbus
Alabama
- - Birmingham
Illinois
- - Chicago
Maryland
- - Baltimore
Michigan
- - Ann Arbor
Minnesota
- - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
What the finished NCT01882504 record still lists
NCT01882504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 37-participant average among 3 other Pyoderma Gangrenosum trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Pyoderma Gangrenosum appearing as the primary indexed condition, and to 1 intervention - of which gevokizumab is the first listed.
NCT01882504 lists 19 locations in 15 states (Texas, Florida, Ohio).
Frequently Asked Questions
What is clinical trial NCT01882504 about?
NCT01882504 is a clinical study titled "Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum". The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
What is the current status of trial NCT01882504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-05. Estimated completion is 2015-10.
What conditions does trial NCT01882504 study?
This clinical trial studies the following conditions: Pyoderma Gangrenosum.
What interventions are being tested in trial NCT01882504?
The interventions under investigation include: gevokizumab (DRUG).
Who is sponsoring clinical trial NCT01882504?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01882504 being conducted?
This trial has 19 study locations across Alabama, Florida, Illinois, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pyoderma Gangrenosum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia